HANA BIOSCIENCES SUBMITS ZENSANA ORAL SPRAY NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION

A A

Hana Biosciences, a biopharmaceutical company focused on advancing cancer care, today announced that the company has submitted a New Drug Application (NDA) for Zensana (ondansetron HCl) Oral Spray to the U.S. Food and Drug Administration seeking marketing approval for the prevention of nausea and vomiting associated with chemotherapy, radiotherapy, and post-operative induced nausea and vomiting. Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060630005096&newsLang=en)